Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Total Non-current Liabilities
All obligations due after more than one year.
Annovis Bio, Inc.NYSE: ANVS
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 82.7% from a year ago
Total non-current liabilities stood at $327K at the end of Q1 FY2026, up 82.7% from a year earlier and down 45.0% from the prior quarter.
Context
- Total non-current liabilities amounted to 2.0% of total assets at the end of Q1 FY2026, up 1.3 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +82.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 595K USD
- Year-over-year change
- -19.3%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 595K | -19.3% |
| FY2024 | 2024-12-31 | 737K | -94.6% |
| FY2023 | 2023-12-31 | 13.68M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 total non-current liabilities of $327K is the lowest of the 6 companies compared; the peer median is $3.33M.
- Its year-over-year change of +82.7% is the highest of 6, against a peer median of -23.9%.
- Total non-current liabilities amounts to 2.0% of total assets for ANVS, versus a peer median of 17.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $64.63M | -7.9% | -22.7% | 60.2% | |
| Mar 2026 | $10.62M | +66.0% | -20.3% | 43.1% | |
| Mar 2026 | $3.33M | -23.9% | -32.3% | 17.4% | |
| Mar 2026 | $1.24M | -33.6% | +82.5% | 3.5% | |
| Jun 2026 | $595K | -98.3% | -1.0% | 1.5% | |
| Mar 2026 | $327K | +82.7% | — | 2.0% | |
| Peer median (excluding ANVS) | $3.33M | -23.9% | -20.3% | 17.4% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.